<DOC>
	<DOCNO>NCT02574650</DOCNO>
	<brief_summary>The purpose study assess early safety performance Mitralign Percutaneous Tricuspid Valve Annuloplasty System ( PTVAS ) treatment symptomatic chronic functional tricuspid regurgitation ( FTR ) . The procedure perform PTVAS device use non-surgical percutaneous approach tricuspid valve repair patient FTR minimum moderate tricuspid regurgitation .</brief_summary>
	<brief_title>Early Feasibility Mitralign Percutaneous Tricuspid Valve Annuloplasty System ( PTVAS ) Also Known TriAlign™ .</brief_title>
	<detailed_description>A prospective , single-arm , multi-center study , enrol symptomatic patient chronic functional tricuspid regurgitation left-sided valve surgery plan . The study include 30 subject 6 site . Follow-up evaluation conduct 2-years post implantation .</detailed_description>
	<mesh_term>Heart Valve Diseases</mesh_term>
	<mesh_term>Tricuspid Valve Insufficiency</mesh_term>
	<criteria>Chronic functional tricuspid regurgitation ( FTR ) minimum moderate tricuspid regurgitation ; ≥18 ≤85 year old ; NYHA II IV ; Symptomatic despite Guideline Directed medical Therapy ( GDMT ) , minimum , patient diuretic use ; LVEF ≥35 % Tricuspid valve annular diameter ≥ 40 mm ( 21 mm/m2 ( Superscript ) ) ≤55 mm ( 29 mm/m2 ( Superscript ) ) Pregnant lactate female ; Severe uncontrolled hypertension ( SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg ) ; Previous tricuspid valve repair replacement ; Severe coronary artery disease ; MI know unstable angina within 30days prior index procedure ; Any PCI within 30 day prior index procedure plan 3 month post index procedure ; Chronic oral steroid use ( ≥6 month ) ; Life expectancy less 12months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>